Subtopic Deep Dive

← Histone Deacetylase Inhibitors Research

HDAC Inhibitors in Neurodegenerative Diseases
Research Guide

What is HDAC Inhibitors in Neurodegenerative Diseases?

HDAC inhibitors in neurodegenerative diseases research examines class I HDACi neuroprotective mechanisms in Alzheimer's, Huntington's, and Parkinson's via alpha-tubulin acetylation and autophagy induction in preclinical models.

Class I HDAC inhibitors like those targeting HDAC2 reverse memory deficits in Alzheimer's mouse models (Kilgore et al., 2009, 710 citations). HDAC2 negatively regulates synaptic plasticity and memory formation (Guan et al., 2009, 1604 citations). Tau acetylation promotes pathological aggregation in neurodegenerative contexts (Cohen et al., 2011, 687 citations). Over 5 key papers from 2007-2012 exceed 600 citations each.

Curated Papers

Key Challenges

Why It Matters

HDAC inhibitors restore cognitive function in Alzheimer's models by reversing contextual memory deficits (Kilgore et al., 2009). They enhance synaptic plasticity via CREB:CBP-dependent transcription, addressing proteostasis failure in aging brains (Vecsey et al., 2007). Valproic acid, an HDACi, shows neuroprotective potential beyond epilepsy (Chateauvieux et al., 2010). These mechanisms support repurposing for Parkinson's and Huntington's protein aggregate clearance.

Key Research Challenges

Isoform Selectivity

Class I HDACs like HDAC2 require selective inhibition to avoid off-target effects in brain tissue (Guan et al., 2009). Broad inhibitors risk toxicity in chronic neurodegenerative dosing (Chateauvieux et al., 2010). Achieving HDAC2-specific blockade remains key for memory restoration (Kilgore et al., 2009).

Blood-Brain Barrier Penetration

Many HDACi fail to cross the blood-brain barrier effectively in neurodegenerative models. Valproic acid achieves CNS levels but with variable efficacy (Chateauvieux et al., 2010). Preclinical translation to humans demands optimized pharmacokinetics.

Long-Term Toxicity

Chronic HDAC inhibition risks epigenetic dysregulation and cancer promotion (Li and Seto, 2016). Balancing neuroprotection against systemic effects challenges clinical advancement (Arrowsmith et al., 2012). Dose-response in aging models needs refinement.

Essential Papers

HDAC2 negatively regulates memory formation and synaptic plasticity

Ji‐Song Guan, Stephen J. Haggarty, Emanuela Giacometti et al. · 2009 · Nature · 1.6K citations

Epigenetic protein families: a new frontier for drug discovery

C.H. Arrowsmith, C. Bountra, Paul V. Fish et al. · 2012 · Nature Reviews Drug Discovery · 1.3K citations

HDACs and HDAC Inhibitors in Cancer Development and Therapy

Yixuan Li, Edward Seto · 2016 · Cold Spring Harbor Perspectives in Medicine · 1.2K citations

Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Post-translational modifications of histones, for example, may play a crucial...

Histone Deacetylase Inhibitors as Anticancer Drugs

Tomáš Eckschlager, Johana Plch, Marie Stiborová et al. · 2017 · International Journal of Molecular Sciences · 1.1K citations

Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene exp...

Histone Deacetylase Inhibitors Enhance Memory and Synaptic Plasticity via CREB: CBP-Dependent Transcriptional Activation

Christopher G. Vecsey, Joshua D. Hawk, K. Matthew Lattal et al. · 2007 · Journal of Neuroscience · 830 citations

Histone deacetylase (HDAC) inhibitors increase histone acetylation and enhance both memory and synaptic plasticity. The current model for the action of HDAC inhibitors assumes that they alter gene ...

Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease

Mark Kilgore, Courtney A. Miller, Daniel M. Fass et al. · 2009 · Neuropsychopharmacology · 710 citations

The acetylation of tau inhibits its function and promotes pathological tau aggregation

Todd J. Cohen, Jing Guo, David Hurtado et al. · 2011 · Nature Communications · 687 citations

Reading Guide

Foundational Papers

Read Vecsey et al. (2007, 830 citations) first for HDACi memory enhancement via CREB; then Guan et al. (2009, 1604 citations) for HDAC2 synaptic roles; Kilgore et al. (2009) for Alzheimer's application.

Recent Advances

Arrowsmith et al. (2012, 1289 citations) for drug discovery frontiers; Cohen et al. (2011, 687 citations) for tau acetylation pathology.

Core Methods

Class I HDAC inhibition in mouse models measures histone acetylation, synaptic plasticity via CREB:CBP, and tau aggregation assays.

How PapersFlow Helps You Research HDAC Inhibitors in Neurodegenerative Diseases

Discover & Search

Research Agent uses searchPapers('HDAC2 Alzheimer\'s mouse model') to retrieve Kilgore et al. (2009), then citationGraph to map 710 citing papers on class I HDACi neuroprotection, and findSimilarPapers to uncover tau acetylation links (Cohen et al., 2011). exaSearch scans 250M+ OpenAlex papers for unpublished preclinical data.

Analyze & Verify

Analysis Agent applies readPaperContent on Guan et al. (2009) to extract HDAC2 synaptic plasticity mechanisms, verifyResponse with CoVe against Vecsey et al. (2007) for CREB pathway consistency, and runPythonAnalysis to plot acetylation levels from extracted datasets using matplotlib. GRADE grading scores evidence strength for Alzheimer's memory reversal claims.

Synthesize & Write

Synthesis Agent detects gaps in blood-brain barrier HDACi studies post-Kilgore et al. (2009), flags contradictions between tau acetylation papers (Cohen et al., 2011), and uses exportMermaid for mechanism diagrams. Writing Agent employs latexEditText for manuscript sections, latexSyncCitations for 1604-citation Guan paper integration, and latexCompile for figure-embedded PDFs.

Use Cases

"Extract acetylation data from HDAC inhibitor Alzheimer's papers and plot dose-response curves"

Research Agent → searchPapers → Analysis Agent → readPaperContent (Vecsey 2007) → runPythonAnalysis (pandas curve fitting, matplotlib plots) → researcher gets CSV data and publication-ready dose-response graphs.

"Draft LaTeX review on HDAC2 in synaptic plasticity with citations"

Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Guan 2009, Kilgore 2009) → latexCompile → researcher gets compiled PDF with synced bibliography and tau mechanism figure.

"Find GitHub code for HDACi tau aggregation simulations"

Research Agent → paperExtractUrls (Cohen 2011) → paperFindGithubRepo → githubRepoInspect → researcher gets verified simulation notebooks linked to tau acetylation models.

Automated Workflows

Deep Research workflow scans 50+ papers via searchPapers on 'HDACi Parkinson\'s autophagy', structures report with GRADE-scored sections on alpha-tubulin acetylation from Guan et al. (2009). DeepScan's 7-step chain verifies Kilgore et al. (2009) Alzheimer's claims against citing works using CoVe checkpoints. Theorizer generates hypotheses on HDAC2:tau interactions from Vecsey (2007) and Cohen (2011) abstracts.

Try Doxa for HDAC Inhibitors in Neurodegenerative Diseases Research

Frequently Asked Questions

What defines HDAC inhibitors in neurodegenerative diseases?

Research focuses on class I HDACi neuroprotective effects via alpha-tubulin acetylation and autophagy in Alzheimer's, Parkinson's, and Huntington's preclinical models.

What are key methods for HDACi neuroprotection?

Mouse models test class I HDAC inhibitors for contextual memory reversal (Kilgore et al., 2009) and CREB:CBP transcription enhancement (Vecsey et al., 2007).

What are the most cited papers?

Guan et al. (2009, 1604 citations) on HDAC2 memory regulation; Kilgore et al. (2009, 710 citations) on Alzheimer's deficits reversal.

What open problems exist?

Isoform-selective HDAC2 inhibitors need better blood-brain barrier penetration and long-term safety data beyond valproic acid (Chateauvieux et al., 2010).